SCHEMBL186200

SCHEMBL186200

CC(C)(C)OC(=O)NC(C)(C=O)C(=O)OC(C)(C)C

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DGAT1 O75907 1/20 0.42
CTSK P43235 3/20 0.37
TDP1 Q9NUW8 1/20 0.34
CA1 P00915 2/20 0.33
CA2 P00918 2/20 0.33
CA7 P43166 2/20 0.33
MAOA P21397 1/20 0.33
MAOB P27338 1/20 0.33
MIF P14174 1/20 0.33
MEN1 O00255 1/20 0.33
GAA P10253 1/20 0.33
KMT2A Q03164 1/20 0.33
KDM4E B2RXH2 1/20 0.32
NPC1 O15118 1/20 0.32
RECQL P46063 1/20 0.32
RAB9A P51151 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
CA12 O43570 2/20 0.32
CA14 Q9ULX7 2/20 0.32
APLNR P35414 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10271620 0.90 DGAT1 (0.45) DGAT1CTSKTDP1CA1CA2
SCHEMBL600677 0.90 DGAT1 (0.45) DGAT1CTSKTDP1CA1CA2
SCHEMBL28824278 0.84 CTSK (0.37) DGAT1CTSKTDP1CA1CA2
SCHEMBL28824277 0.84 CTSK (0.37) DGAT1CTSKTDP1CA1CA2
SCHEMBL293062 0.77 CTSK (0.40) DGAT1CTSKTDP1CA1CA2
SCHEMBL10883543 0.75 CTSK (0.39) DGAT1CTSKTDP1CA1CA2
SCHEMBL3374338 0.73 CA1 (0.40) DGAT1CTSKTDP1CA1CA2
SCHEMBL12691730 0.73 CA1 (0.42) CTSKTDP1CA1CA2CA7
SCHEMBL1374814 0.72 DGAT1 (0.52) DGAT1TDP1CA1CA2CA7
SCHEMBL132657 0.71 DGAT1 (0.42) DGAT1CTSKTDP1CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8580747-B2 Cyclic natriuretic peptide constructs PALATIN TECHNOLOGIES, INC. (US) 2013-11-12 US disclosed
US-8580746-B2 Amide linkage cyclic natriuretic peptide constructs PALATIN TECHNOLOGIES, INC. (US) 2013-11-12 US disclosed
US-8580747-B2 Cyclic natriuretic peptide constructs PALATIN TECHNOLOGIES, INC. (US) 2013-11-12 US disclosed
EP-2001518-B1 CYCLIC NATRIURETIC PEPTIDE CONSTRUCTS PALATIN TECHNOLOGIES INC (US) 2013-07-10 EP disclosed
US-8114844-B2 Linear and cyclic melanocortin receptor-specific peptidomimetics PALATIN TECHNOLOGIES, INC. (US) 2012-02-14 US disclosed
EP-2004352-B1 AMINO ACID SURROGATES FOR PEPTIDIC CONSTRUCTS PALATIN TECHNOLOGIES INC (US) 2012-01-04 EP disclosed
US-20110263818-A1 Peptidic Constructs with Amino Acid Surrogates PALATIN TECHNOLOGIES, INC. (US) 2011-10-27 US disclosed
US-7964181-B2 Amino acid surrogates for peptidic constructs PALATIN TECHNOLOGIES, INC. (US) 2011-06-21 US disclosed
US-7795221-B2 Linear natriuretic peptide constructs PALATIN TECHNOLOGIES, INC. (US) 2010-09-14 US disclosed
US-20100075895-A1 Cyclic Natriuretic Peptide Constructs PALATIN TECHNOLOGIES, INC. (US) 2010-03-25 US disclosed
EP-2004633-A2 LINEAR NATRIURETIC PEPTIDE CONSTRUCTS Palatin Technologies, Inc. (US) 2008-12-24 EP disclosed
EP-2004352-A2 AMINO ACID SURROGATES FOR PEPTIDIC CONSTRUCTS Palatin Technologies, Inc. (US) 2008-12-24 EP disclosed
EP-2001518-A2 CYCLIC NATRIURETIC PEPTIDE CONSTRUCTS Palatin Technologies, Inc. (US) 2008-12-17 EP disclosed
WO-2007115164-A9 AMINO ACID SURROGATES FOR PEPTIDIC CONSTRUCTS PALATIN TECHNOLOGIES INC (US) 2007-11-29 WO disclosed
US-20070265206-A1 Cyclic Natriuretic Peptide Constructs PALATIN TECHNOLOGIES, INC. (US) 2007-11-15 US disclosed
US-20070260040-A1 Amino Acid Surrogates for Peptidic Constructs PALATIN TECHNOLOGIES, INC. (US) 2007-11-08 US disclosed
WO-2007115182-A2 LINEAR NATRIURETIC PEPTIDE CONSTRUCTS PALATIN TECHNOLOGIES, INC. (US) 2007-10-11 WO disclosed
WO-2007115175-A2 CYCLIC NATRIURETIC PEPTIDE CONSTRUCTS PALATIN TECHNOLOGIES, INC. (US) 2007-10-11 WO disclosed
WO-2007115164-A2 AMINO ACID SURROGATES FOR PEPTIDIC CONSTRUCTS PALATIN TECHNOLOGIES, INC. (US) 2007-10-11 WO disclosed
US-20070232546-A1 Linear Natriuretic Peptide Constructs PALATIN TECHNOLOGIES, INC. (US) 2007-10-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110263818-A1 Peptidic Constructs with Amino Acid Surrogates ARGLU1, QRFPR, ARG1 DGAT1 4730/4885CTSK 1454/4885TDP1 3303/4885
US-20070265206-A1 Cyclic Natriuretic Peptide Constructs NPR1, NPR3, NPPA DGAT1 4797/4885CTSK 2097/4885TDP1 3318/4885
US-20070260040-A1 Amino Acid Surrogates for Peptidic Constructs ARGLU1, ARG1, QRFPR DGAT1 4761/4885CTSK 1372/4885TDP1 4227/4885
US-20070232546-A1 Linear Natriuretic Peptide Constructs NPR1, NPR3, NPPA DGAT1 4816/4885CTSK 2306/4885TDP1 2975/4885
US-20100075895-A1 Cyclic Natriuretic Peptide Constructs NPR1, NPR3, NPPA DGAT1 4797/4885CTSK 2097/4885TDP1 3318/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.